Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Feb 13;6:50–58. doi: 10.1016/j.ebiom.2016.02.024

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 The Authors

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.

PMC Copyright notice

Fig. 4 — CSF-1R blockade potentiates antitumor responses to checkpoint blockade. (a) Mean tumor growth and overall survival of B16-IDO tumor-bearing mice treated with PLX647 and/or aCTLA-4 + aPD-1. (b) B16-IDO tumors from mice treated with PLX647 and/or aCTLA-4 + aPD-1 were harvested 2 weeks after tumor cell inoculation and analyzed for absolute numbers of CD45⁺ cells and T cells per gram of tumor. (c) Infiltration of CD8⁺ T cells, CD4⁺ Foxp3⁻ T cells and CD4⁺ Foxp3⁺ Tregs gated on the CD45⁺ population. (d) Representative dot plots showing IFNγ expressing CD8⁺ T cells in response to in vitro stimulation with DCs. (e) Effector T cells to Treg ratios in tumors. (f) Relative percentage of total CD11b⁺ cells and CD11b⁺ Gr1^int subsets of CD45⁺ TILs. (g) Survival curves for B16-IDO tumor-bearing mice treated with PLX647 and/or aCTLA-4 + aPD-1 plus depleting antibodies for CD8 and CD4 or a corresponding dose of IgG isotype control. (h) Mean tumor growth and overall survival of CT26 tumor-bearing mice treated with PLX647 and/or aCTLA-4 + aPD-1. Data are mean ± SEM of 3 independent experiments with 5 mice/group.